Literature DB >> 1115577

Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs.

R P Granacher, R J Baldessarini.   

Abstract

We reviewed the use of physostigmine in the diagnosis and management of acute toxic psychosis due to drugs with anticholinergic properties. The syndrome of agitation and toxic confusional psychosis associated with peripheral signs of cholinergic blockade is produced by several plant toxins, antispasmodics, ophthalmic preparations, and certain proprietary sedatives, as well as antiparkinson medications, antidepressants, and some antipsychotic drugs. Physostigmine, uniquely among the available reversible anticholinesterase agents, can pass the blood-brain barrier to exert central as well as peripheral cholinomimetic actions to reverse this syndrome. Psychiatrists should make more use of this safe, specific, rapid, and effective treatment for anticholinergic drug toxicity, and should particularly be alert to reversible anticholinergic brain syndromes associated with antidepressants and antiparkinson medications, and even with antipsychotic medications.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1115577     DOI: 10.1001/archpsyc.1975.01760210109008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  20 in total

Review 1.  Drug-induced cognitive impairment in the elderly.

Authors:  A R Moore; S T O'Keeffe
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

Review 2.  Clinical pharmacology of old age syndromes.

Authors:  C Broadhurst; K C M Wilson; M T Kinirons; A Wagg; J K Dhesi
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

3.  [Central anticholinergic syndrome and apnea after general anaesthesia. A rare manifestation of the central anticholinergic syndrome].

Authors:  I Senne; C Zourelidis; D Irnich; M Kurz; T Hummel; B Zwissler
Journal:  Anaesthesist       Date:  2003-07-10       Impact factor: 1.041

4.  The management of neuroleptic-induced CNS effects.

Authors:  B F Hoffman; M V Seeman
Journal:  Can Fam Physician       Date:  1981-10       Impact factor: 3.275

Review 5.  Delirium in hospitalized elderly.

Authors:  J Francis; W N Kapoor
Journal:  J Gen Intern Med       Date:  1990 Jan-Feb       Impact factor: 5.128

6.  Experiences with physostigmine in the reversal of adverse post-anaesthetic effects.

Authors:  J Brebner; L Hadley
Journal:  Can Anaesth Soc J       Date:  1976-11

7.  Acute poisoning: an update.

Authors:  C W Raymond
Journal:  Can Med Assoc J       Date:  1977-08-20       Impact factor: 8.262

Review 8.  Current antidepressant drugs: their clinical use.

Authors:  L E Hollister
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

9.  Amoxapine and amitriptyline. II. Specificity of cognitive effects during brief treatment of depression.

Authors:  D M McNair; R J Kahn; L M Frankenthaler; L L Faldetta
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Methoscopolamine inhibition of sleep-related growth hormone secretion. Evidence for a cholinergic secretory mechanism.

Authors:  W B Mendelson; N Sitaram; R J Wyatt; J C Gillin; L S Jacobs
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.